Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to -$1.3 billion.

  • Rhythm Pharmaceuticals' Retained Earnings fell 1729.86% to -$1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year decrease of 1729.86%. This contributed to the annual value of -$1.2 billion for FY2024, which is 2912.61% down from last year.
  • As of Q3 2025, Rhythm Pharmaceuticals' Retained Earnings stood at -$1.3 billion, which was down 1729.86% from -$1.3 billion recorded in Q2 2025.
  • Rhythm Pharmaceuticals' Retained Earnings' 5-year high stood at -$415.6 million during Q1 2021, with a 5-year trough of -$1.3 billion in Q3 2025.
  • Its 5-year average for Retained Earnings is -$840.4 million, with a median of -$808.9 million in 2023.
  • Its Retained Earnings has fluctuated over the past 5 years, first tumbled by 1452.37% in 2021, then crashed by 3997.48% in 2022.
  • Over the past 5 years, Rhythm Pharmaceuticals' Retained Earnings (Quarter) stood at -$528.9 million in 2021, then tumbled by 34.24% to -$710.1 million in 2022, then fell by 26.01% to -$894.7 million in 2023, then fell by 29.13% to -$1.2 billion in 2024, then fell by 12.9% to -$1.3 billion in 2025.
  • Its Retained Earnings was -$1.3 billion in Q3 2025, compared to -$1.3 billion in Q2 2025 and -$1.2 billion in Q1 2025.